Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

Company Overview - Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines to improve patients' lives through innovative science and delivery technologies [4] - The company is developing orally administered products to deliver complex molecules, providing alternatives to invasive therapies [4] - Currently, Aquestive has four commercialized products marketed by its licensees and collaborates with other pharmaceutical companies to bring new molecules to market [4] Leadership Change - Sherry Korczynski has been promoted from Senior Vice President of Sales and Marketing to Chief Commercial Officer effective July 22, 2025 [1] - Her promotion is attributed to her exceptional track record in commercial leadership, particularly in the allergy market, and her strategic oversight of the EpiPen brand at Mylan [2] - Korczynski joined Aquestive in February 2024 and has over two decades of experience in commercial and launch roles across various pharmaceutical companies [2] Product Development - Anaphylm™ (epinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug candidate that is designed to be the first and only device-free, orally delivered epinephrine product [3] - The product is small, weighing less than an ounce, and dissolves on contact without the need for water or swallowing [3] - Anaphylm has been conditionally approved by the U.S. Food and Drug Administration (FDA), with final approval dependent on the product candidate's approval [3] Market Positioning - Anaphylm is positioned to potentially redefine anaphylaxis care, with a focus on successful launch and delivery to patients in the U.S. and abroad [3] - The company aims to leverage Korczynski's deep market knowledge and experience to drive its global commercial strategy for Anaphylm [2]